sunitinib hydrochloride

Poland

Drugs containing this active substance

  • SUNITINIB PHARMASCIENCE

    The medicine is used in adults for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (mRCC), and progressive pancreatic neuroendocrine tumors (pNET) that cannot be surgically removed.

    Form: capsules, hard

    Active substance Dosage
    sunitinib hydrochloride 13.646 mg

    ATC: L01XE04

    Manufacturer: Bluepharma Pharmaceutical Industry, S.A.

  • The medicinal product is used in adults for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (mRCC), and progressive, unresectable pancreatic neuroendocrine tumors (pNET).

    Form: capsules, hard

    Active substance Dosage
    sunitinib hydrochloride 27.293 mg

    ATC: L01XE04

    Manufacturer: Bluepharma Pharmaceutical Industry, S.A.

  • The medicine is used in adults for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (mRCC), and pancreatic neuroendocrine tumors (pNET) that are in the progressive phase and cannot be surgically removed.

    Form: capsules, hard

    Active substance Dosage
    sunitinib hydrochloride 40.939 mg

    ATC: L01XE04

    Manufacturer: Bluepharma Pharmaceutical Industry, S.A.

  • The medicine is used in adults for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (mRCC), and progressive pancreatic neuroendocrine tumors (pNET) that cannot be surgically removed.

    Form: capsules, hard

    Active substance Dosage
    sunitinib hydrochloride 54.585 mg

    ATC: L01XE04

    Manufacturer: Bluepharma Pharmaceutical Industry, S.A.